Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
1.96
USD
|
0.00%
|
|
+2.08%
|
-19.34%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,113
|
486.7
|
119.9
|
92.47
|
75.12
|
-
|
-
|
Enterprise Value (EV)
1 |
927.9
|
232.9
|
-125.3
|
-54.95
|
-179
|
75.12
|
75.12
|
P/E ratio
|
-20.5
x
|
-8.74
x
|
-1.25
x
|
-0.79
x
|
-0.73
x
|
-0.94
x
|
-3.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
11.2
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
11.2
x
|
EV / EBITDA
|
-46.4
x
|
-3.67
x
|
1.34
x
|
-
|
1.34
x
|
-0.58
x
|
-0.58
x
|
EV / FCF
|
-35.1
x
|
-5.21
x
|
1.7
x
|
0.54
x
|
1.48
x
|
-0.54
x
|
-0.52
x
|
FCF Yield
|
-2.85%
|
-19.2%
|
58.8%
|
184%
|
67.6%
|
-186%
|
-193%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32,485
|
37,351
|
37,829
|
38,055
|
38,327
|
-
|
-
|
Reference price
2 |
34.25
|
13.03
|
3.170
|
2.430
|
1.960
|
1.960
|
1.960
|
Announcement Date
|
3/25/21
|
3/24/22
|
3/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6.714
|
EBITDA
1 |
-
|
-19.99
|
-63.54
|
-93.17
|
-
|
-133.6
|
-129.8
|
-130.4
|
EBIT
1 |
-5.449
|
-20
|
-64.02
|
-94.02
|
-127.1
|
-129.7
|
-151.1
|
-160.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,392.51%
|
Earnings before Tax (EBT)
1 |
-
|
-19.96
|
-54.85
|
-95.64
|
-117.7
|
-126
|
-144.7
|
-154.7
|
Net income
1 |
-
|
-19.96
|
-54.85
|
-95.64
|
-117.7
|
-123.8
|
-144.7
|
-154.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,304.64%
|
EPS
2 |
-1.427
|
-1.670
|
-1.490
|
-2.530
|
-3.090
|
-2.677
|
-2.084
|
-0.5350
|
Free Cash Flow
1 |
-
|
-26.43
|
-44.67
|
-73.61
|
-101.1
|
-121
|
-139.7
|
-145.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,163.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/24/20
|
3/25/21
|
3/24/22
|
3/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.83
|
-18.78
|
-23.39
|
-23.57
|
-24.13
|
-22.93
|
-29.77
|
-31.64
|
-35.04
|
-30.64
|
-31.98
|
-32.36
|
-32.52
|
-30.55
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.67
|
-16.34
|
-20.98
|
-24.34
|
-20.19
|
-30.14
|
-27.82
|
-29.6
|
-32.97
|
-27.28
|
-29.6
|
-30
|
-30.3
|
-26.95
|
Net income
1 |
-15.67
|
-16.34
|
-20.98
|
-24.34
|
-20.19
|
-30.14
|
-27.82
|
-29.6
|
-32.97
|
-27.28
|
-30.32
|
-31.07
|
-31.76
|
-30.01
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4200
|
-0.3700
|
-0.5600
|
-0.6500
|
-0.5300
|
-0.7900
|
-0.7300
|
-0.7800
|
-0.8700
|
-0.7100
|
-0.7980
|
-0.8100
|
-0.8160
|
-0.6360
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/24/22
|
5/12/22
|
8/15/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/10/23
|
11/9/23
|
2/22/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
185
|
254
|
245
|
147
|
254
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-26.4
|
-44.7
|
-73.6
|
-101
|
-121
|
-140
|
-145
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.32
|
1.57
|
1.14
|
0.3
|
4
|
4
|
4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
59.57%
|
Announcement Date
|
3/25/21
|
3/24/22
|
3/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
1.96
USD Average target price
7.417
USD Spread / Average Target +278.40% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.34% | 75.12M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|